BioInvent International ABShs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.12.20	BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc. (PR Newswire)
23.12.20	BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc. (PR Newswire)
09.12.20	Nomination Committee appointed for BioInvent International's Annual General Meeting 2021 (PR Newswire)
09.12.20	Nomination Committee appointed for BioInvent International's Annual General Meeting 2021 (PR Newswire)
07.12.20	Record date for reverse share split in BioInvent International determined (PR Newswire)
07.12.20	Record date for reverse share split in BioInvent International determined (PR Newswire)
27.11.20	Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020 (PR Newswire)
27.11.20	Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020 (PR Newswire)
27.11.20	BioInvent strengthens Investor Relations (PR Newswire)
27.11.20	BioInvent strengthens Investor Relations (PR Newswire)
26.11.20	BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10 (PR Newswire)
26.11.20	BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10 (PR Newswire)
09.11.20	BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting (PR Newswire)
09.11.20	BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting (PR Newswire)
09.11.20	BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35th Anniversary Annual Meeting (PR Newswire)
09.11.20	BioInvent presents new preclinical data on BI-1808, a first-in-class anti-TNFR2 antibody at the SITC 35th Anniversary Annual Meeting (PR Newswire)
04.11.20	BioInvent presents promising new clinical and preclinical data on anti-FcγRllB antibody, BI-1206, at the ASH Annual Meeting (PR Newswire)
04.11.20	BioInvent presents promising new clinical and preclinical data on anti-FcγRllB antibody, BI-1206, at the ASH Annual Meeting (PR Newswire)
27.10.20	Notice to Extraordinary General Meeting in BioInvent International AB (PR Newswire)
27.10.20	Notice to Extraordinary General Meeting in BioInvent International AB (PR Newswire)
27.10.20	BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region (PR Newswire)
27.10.20	BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region (PR Newswire)
26.10.20	CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial (PR Newswire)
26.10.20	CTA approval of BioInvent's BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial (PR Newswire)
22.10.20	BioInvent receives €2 million milestone from Daiichi Sankyo (PR Newswire)
22.10.20	BioInvent receives €2 million milestone from Daiichi Sankyo (PR Newswire)
15.10.20	BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting (PR Newswire)
15.10.20	BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting (PR Newswire)
27.08.20	BioInvent Interim Report January 1 - June 30, 2020 (PR Newswire)
27.08.20	BioInvent Interim Report January 1 - June 30, 2020 (PR Newswire)
21.08.20	Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020 (PR Newswire)
21.08.20	Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020 (PR Newswire)
22.07.20	BioInvent's BI-1206 could improve treatment in several cancers (PR Newswire)
22.07.20	BioInvent's BI-1206 could improve treatment in several cancers (PR Newswire)
13.07.20	BioInvent to Host Key Opinion Leader Call on Enhancing Checkpoint Inhibitors for the Treatment of Solid Cancers (PR Newswire)
13.07.20	BioInvent to Host Key Opinion Leader Call on Enhancing Checkpoint Inhibitors for the Treatment of Solid Cancers (PR Newswire)
01.07.20	BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc. (PR Newswire)
01.07.20	BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc. (PR Newswire)
30.06.20	BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL (PR Newswire)
30.06.20	BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL (PR Newswire)
23.06.20	BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors (PR Newswire)
23.06.20	BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors (PR Newswire)
22.06.20	BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies (PR Newswire)
22.06.20	BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies (PR Newswire)
18.06.20	Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020 (PR Newswire)
18.06.20	Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020 (PR Newswire)
15.05.20	BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors (PR Newswire)
15.05.20	BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors (PR Newswire)
15.05.20	BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development (PR Newswire)
15.05.20	BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu BioInvent International ABShs

Aktien Top/Flop

Meistgelesene Nachrichten